source
- Roche CEO says stance on $1.5B Poseida acquisition unchanged despite dropping one CAR-T programRoche bought Poseida in 2024 for $1.5 billion to secure its off-the-shelf CAR-T platform and strengthen its cell-therapy portfolio. During the third-quarter earnings call, the company said it has…
- GSK receives FDA approval for hepatitis B therapy that expands functional cure ratesGSK announced that the U.S. Food and Drug Administration has granted approval for its hepatitis B drug. The agency said the treatment can achieve functional cures in a larger proportion of patient…